Search Results
Jennifer R. Brown, MD, PhD: The Changing Definition of “High-Risk” CLL
ASH Impact Series: Jennifer Brown, MD, PhD - Treating High-Risk CLL
Conversations with Innovators: Jennifer R. Brown, MD, PhD
Dr. Jennifer Brown on Mutations and Targets in CLL
ASH22: Jennifer Brown, MD, PhD | Dana-Farber Cancer Institute
Dr. Jennifer Brown on the Role of FCR in CLL
Dr. Jennifer Brown on Gauging Response in CLL
Dr Jennifer Brown on the Role of Genomic Sequencing in CLL
Dr. Jennifer Brown Discusses Single Agents in CLL
Jennifer R. Brown, MD, PhD: Ibrutinib and Atrial Fibrillation Risk in RCTs
Dr. Jennifer Brown on RESONATE 2 Trial in CLL
Dr. Brown on the Development of Treatments for CLL
